Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;25(4):326-33.
doi: 10.1007/s11606-009-1228-x. Epub 2010 Jan 20.

Diabetes and drug-associated hyperkalemia: effect of potassium monitoring

Marsha A Raebel  1 , Colleen Ross, Stanley Xu, Douglas W Roblin, Craig Cheetham, Christopher M Blanchette, Gwyn Saylor, David H Smith
Affiliations

Diabetes and drug-associated hyperkalemia: effect of potassium monitoring

Marsha A Raebel et al. J Gen Intern Med. 2010 Apr.

Abstract

Background: Renin-angiotensin-aldosterone system (RAAS) inhibitors are associated with hyperkalemia, but there is little evidence demonstrating patients who receive potassium monitoring have a lower rate of hyperkalemia.

Objective: To evaluate the association between potassium monitoring and serious hyperkalemia-associated adverse outcomes among patients with diabetes newly initiating RAAS inhibitor therapy.

Design: Retrospective observational study.

Participants: Patients with diabetes without end-stage renal disease initiating RAAS inhibitor therapy between 2001 and 2006 at three integrated health care systems.

Measurements: Potassium monitoring and first hyperkalemia-associated adverse event during the initial year of therapy. Hyperkalemia-associated adverse events included hospitalizations, emergency department visits or deaths within 24 h of hyperkalemia diagnosis and/or diagnostic potassium >or=6 mmol/l. Incidence rates were calculated in person-years (p-y). We used inverse probability propensity score weighting to adjust for differences between patients with and without monitoring; Poisson regression was used to obtain adjusted relative risks.

Results: A total of 19,391 of 27,355 patients (71%) received potassium monitoring. Serious hyperkalemia-associated events occurred at an incidence rate of 10.2 per 1,000 p-y. Compared to patients without monitoring, adjusted relative risk of hyperkalemia-associated adverse events among all patients with monitoring was 0.50 (0.37, 0.66); in the subset of patients who also had chronic kidney disease (n = 2,176), adjusted relative risk was 0.29 (0.18, 0.46).

Conclusions: Patients prescribed RAAS inhibitors who have both diabetes and chronic kidney disease and receive potassium monitoring are less likely to experience a serious hyperkalemia-associated adverse event compared to similar patients who did not receive potassium monitoring. This evidence supports existing consensus-based guidelines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection of study patients.
See this image and copyright information in PMC

References

    1. Brenner BM, Cooper ME, Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. doi: 10.1056/NEJMoa011161. - DOI - PubMed
    1. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004–1010. doi: 10.1016/S0140-6736(02)08090-X. - DOI - PubMed
    1. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301. - DOI - PubMed
    1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. - DOI - PubMed
    1. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;39(suppl 1):S94–S98. - PubMed

Publication types

MeSH terms